MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

—First patents to cover the fundamental processes for accessing
the human gut microbiome as biotherapeutics—

—MaaT Pharma’s microbiome sample collection and administration
devices receive CE mark for use in collecting and administrating
gut-derived samples as biotherapeutics to patients—

LYON, France–(BUSINESS WIRE)–MaaT Pharma announced today that the Institut National de la Propriété
Industrielle (INPI), the French Patent Office, has issued three new
patents to the company covering its sample collection device and the
overall processes associated with obtaining, processing, storing and
administering human gut samples, ensuring that the highest quality of
microbiota is present in MaaT Pharma’s biologic drugs. In addition, the
patents cover an innovative process to freeze-dry samples preserving the
viability and taxonomic profile of the microbiome and enabling the
development of an oral formulation. These patented processes developed
under a five year research collaboration with the French National
Institute for Agricultural Research (INRA) are a fundamental part of
MaaT Pharma’s integrated Microbiome Restoration Biotherapeutic (MMRB)
platform and have a broad applicability in treating dysbiosis-related
diseases.

“These patents and the CE mark received for our devices solidify the
company as a leader in developing microbiome-based therapeutics that
have the highest quality, diversity and richness in the microbiota for
both our current formulation and the development of an oral form,” said
Hervé Affagard, CEO and Co-founder of MaaT Pharma. “Our lead
therapeutic, MaaT013, developed using our MMRB platform, has already
yielded promising safety data in our ongoing Phase 2 clinical trial
called HERACLES, in patients with steroid-resistant acute
Graft-versus-Host-Disease, a severe complication following hematopoietic
stem cell transplantation. Trial progress and enrollment remain on
schedule.”

Philippe Mauguin, CEO of INRA commented, “MaaT Pharma has raised the bar
for creating microbial biotherapeutics and these patents include
pioneering research from Joël Doré, the company’s scientific advisor and
research director at INRA, who is world-renowned for his work on
host-microbiome interactions. Our partnership with the company started
at its inception and we are fortunate to be involved with a company
pushing the boundaries of developing safe and effective microbial
therapies for patients.”

The IP provides coverage until at least 2035 and includes:

Patent FR 1553721: The design and applicability of the device
used to collect stool samples from individuals is broadly covered by
this patent and is the first device in the world to receive CE mark for
the method of sample collection and processing.

Patent FR 1553716: This patent, co-owned by MaaT Pharma and INRA,
covers the composition and the application of the cryoprotectant used in
MaaT Pharma’s proprietary production process that helps to preserve the
full diversity of the gut microbiome.

Patent FR 1562750: This patent, co-owned by MaaT Pharma and INRA,
set the baseline of MaaT Pharma’s innovative method to freeze-dry a
microbiome sample is a unique approach to generate microbiome-based
capsule formulations that maintain a high viability of the microbiota.

The three above-mentioned granted patents are also under examination
through PCT international patent applications in important global
markets. The company will continue to pursue the grant of additional
patents covering their therapeutic products and technologies. The Class
II CE mark covers MaaT Pharma’s system of devices, including its device
enabling the storage of material and subsequent administration to the
patient with the highest level of safety.

About MaaT Pharma
MaaT Pharma, a clinical stage company, has
established the most complete approach to restoring patient-microbiome
symbiosis to improve survival outcomes in life-threatening diseases.
Committed to treating blood cancers and Graft-versus-Host-Disease, a
serious complication of allogeneic stem cell transplantation, MaaT
Pharma has already achieved proof of concept in acute myeloid leukemia
patients. Supporting the further expansion of our pipeline into larger
indications, we have built a powerful discovery and analysis platform to
evaluate drug candidates, determine novel disease targets and identify
biomarkers for microbiome-related conditions. Our therapeutics are
produced through a standardized cGMP manufacturing and quality control
process to safely deliver the full diversity of the microbiome. MaaT
Pharma benefits from the commitment of world-leading scientists and
established relationships with regulators to spearhead microbiome
treatment integration into clinical practice.

Contacts

For MaaT Pharma
Hervé Affagard, CEO
Phone: +33 (0)4
2829 1400
E-Mail: [email protected]

Media
Requests for MaaT Pharma
Dr. Stephanie May or Dr. Jacob Verghese
Trophic
Communications
Phone: +49 89 23 88 77 30 or +49 171 185 56 82
E-Mail:
[email protected] or [email protected]